WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406482
Description: CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
MedKoo Cat#: 406482
Chemical Formula: C26H27F4N7O2
Exact Mass: 545.21624
Molecular Weight: 545.53189
Elemental Analysis: C, 57.24; H, 4.99; F, 13.93; N, 17.97; O, 5.87
Synonym: CNX2006; CNX 2006; CNX-2006.
IUPAC/Chemical Name: N-(3-((2-((4-((1-(2-fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide
InChi Key: BFSRTTWIPACGMI-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H27F4N7O2/c1-3-23(38)33-16-5-4-6-17(11-16)34-24-20(26(28,29)30)13-31-25(36-24)35-21-8-7-18(12-22(21)39-2)32-19-14-37(15-19)10-9-27/h3-8,11-13,19,32H,1,9-10,14-15H2,2H3,(H,33,38)(H2,31,34,35,36)
SMILES Code: C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(NC4CN(CCF)C4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O
CNX-2006 is a Me-Too version of CO-1686, which structures are compared as below: